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Herpes  simplex  virus  (HSV)  is  one  of  the most  regular  human  pathogens,  being  a public  health  problem,
and  causal  agent  of  several  diseases.  Poliovirus  (PV)  is an enteric  virus  and  about  1%  of  infected  individuals
develop  paralytic  poliomyelitis  due to viral  invasion  of  the  central  nervous  system  and  destruction  of
motor neurons.  This  work  evaluated  the  activity  of  a sulfated  polysaccharide  of  Caesalpinia  ferrea  (SPLCf)  in
HSV  and  PV  replication.  The  antiviral  effect  of SPLCf  at varying  concentrations  was  tested  by plaque  assayeywords:
ntiviral
aesalpinia ferrea
ulfated polysaccharide
erpesvirus
under  several  protocols,  such  as time-of-addition,  adsorption  and  penetration  inhibition  and  virucidal.
Syntheses  of viral  protein  and  nucleic  acid  were  also monitored  by  the immunoﬂuorescence  assay  and
PCR.  The  SPLCf  inhibited  virus  adsorption  and  steps  after  penetration,  and  inhibited the  synthesis  of  viral
protein.  Virucidal  effect  was  also shown  and  nucleic  acid  synthesis  was concurrent  with  positive  results.
Our  ﬁndings  suggested  that  the substance  with low  toxicity  represent  a potential  viral  inhibitor.oliovirus
. Introduction
The herpes simplex virus type 1 (HSV-1), a member of the
erpesviridae family and Simplexvirus genus, is a double-stranded
NA virus, enveloped and possesses the ability to remain latent
n ganglia near the site of infection [1]. Is one of the most regular
uman pathogens, being a public health problem, and causal
gent of several diseases, estimated to occur in 40–80% of world
opulation and approximately 90% of people between 20 and
0 years have antibodies against HSV-1 [2,3]. Moreover, a small
raction of patients with HSV-1 infection develops more serious
iseases of the CNS, the most notable of which is encephalitis.
he yearly incidence of HSV-1 encephalitis has been estimated
t 2–4 cases/one million individuals [4–6]. In Brazil, the HSV-1 is
he most common causative agent of sporadic viral encephalitis
n adults [7]. Immuno compromised individuals and the recipients
f organ transplantations are at high risk for increased sever-
ty of HSV-1 infection. The most of the treatments for HSV are
ased on nucleoside analogs of guanine, for example, acyclovir
ACV). However, widespread use of ACV has shown HSV develops
Abbreviations: SPLCf, Caesalpinia ferrea sulfated polysaccharide; HSV, herpes
implex virus; PV, poliovirus.
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resistance through mutations in genes coding for thymidine kinase
or for DNA polymerase [8]. Therefore, it is important to develop
new antiviral drugs with different mechanisms of action which
could be a substitute or a complement for acyclovir.
Poliovirus type 1 (PV-1), a member of the Picornaviridae family
and Enterovirus genus, is a positive single-stranded RNA non-
enveloped virus. It is an enteric virus and about 1% of infected
individuals develop paralytic poliomyelitis due to viral invasion of
the central nervous system and destruction of motor neurons [9].
Beyond its medical and epidemiological importance, poliovirus is
one of the best understood models of non-enveloped RNA virus,
including for the development of new drugs. Currently, poliovirus
is under control in most part of the world due to vaccines. Despite
the extensive efforts to eradicate the virus, the disease remains
endemic in some countries in Africa and Asia, with 1294 cases
reported in 2010 [10], and, therefore, represents a major threat
for the rest of the world. There is not a speciﬁc drug for the
treatment of polio, but, there are compounds capable of block-
ing viral uncoating and/or viral adsorption on cell receptors, such
as disoxaril and pleconaril [11]. Nevertheless, the development of
naturals anti-poliovirus drugs that combine low toxicity and selec-
tivity are required.In recent years, compounds originated from natural sources
have been investigated and many of them have shown promising as
antivirals [12]. These substances have been shown to interact with
several viral targets, ranging from the adsorption of virus to the
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ost cell until the release of new viral particles, which may  result
n complementary mechanisms of action to the existing antiviral
rugs [13].
Many compounds having potent anti-viral activity in cell cul-
ures have been detected. Among these anti-viral substances,
nionic polysaccharides from natural sources and of synthetic ori-
in are noteworthy [14,15]. It was suggested that these negatively
harged molecules, exert their inhibitory effect by interacting with
he positive charges on the virus or on the cell surface, thereby,
reventing the entry of the virus into the host cells [14].
The Caesalpinia ferrea is a native arboreal species of Brazil, pop-
larly known as pau-ferro or jucá. The bark, seeds, roots and fruits
re used in Brazilian folk medicine with several pharmacologi-
al applications. The methanol extract of C. ferrea fruits has been
emonstrated effective against oral pathogens Streptococcus sp. and
andida albicans [16]. Moreover, ethanol and methanol extracts,
nd triterpenoids from fruits and seeds of different species of Cae-
alpinia presented similar effect against several Gram-positive and
negative bacteria [17,18]. Although the antimicrobial effect of C.
errea has been shown for bacteria and fungus infections, none
as been done concerning its antiviral activity. In this work, we
elated the activity of an aqueous solution of a sulfated derivative
olysaccharide from C. ferrea against HSV and PV, in vitro.
. Materials and methods
.1. Compound
The polysaccharide of C. ferrea Mart ex Tul var ferrea (Voucher
ample 44695) was obtained from the aqueous extraction from the
eeds [19] and the sulfation was performed, as previously described
20,21]. The galactomannan (300 mg)  was allowed to swell in pyri-
ine:formamide (50:10) (v/v) with stirring at 25 ◦C (12 h) until
he ﬁnely dispersed suspension was obtained. After the reaction,
he mixture was  cooled to 4 ◦C and chlorosulfonic acid (4 ml)  was
lowly added to the mixture with stirring over 24 h at 4 ◦C. The
esulting solution was neutralized with a saturated NaHCO3 solu-
ion, dialyzed (molecular weight cutoff 8–12 kDa) for 120 h against
istilled water and then centrifuged for 25 min. Three consecutive
ulfations were carried out and the sulfated derivative was col-
ected after lyophilization. The degree of sulfation (DS = 8.7%) was
etermined by elemental analysis. The C. ferrea sulfated polysac-
haride (SPLCf) stock solution was prepared by dissolving in ultra
ure water.
SPLCf was characterized by 13C, 1H NMR  and FT-IR. 13C and
H NMR  spectra of 2.5% (w/v) solution in D2O were recorded at
53 K on a Fourier transform Brucker Avance-DRX 500 spectrom-
ter with an inverse multinuclear gradient probe-head equipped
ith z-shielded gradient coils, and with Silicon Graphics. Sodium
,2-dimethylsilapentane-5-sulphonate (DSS) was used as the inter-
al standard (0.00 ppm for 1H). The Fourier transform IR spectrum
FT-IR) was recorded with a Perkin Elmer 16 PC spectrometer,
etween 600 and 1400 cm−1. The spectrum was obtained from 20
cans. The sample was analyzed as KBr pellet.
.2. Cells and virus
HEp-2 cells (human larynx epithelial cells carcinoma, ATCC CCL-
3), used throughout, were grown in Dulbecco’s modiﬁed Eagle’s
edium (DMEM), supplemented with 10% fetal bovine serum
Invitrogen – Gibco, USA), 100 IU/ml penicillin (Novafarma Indús-
ria Farmacêutica, BR), 100 g/ml streptomycin (Gibco BRL, USA)
nd 2.5 g/ml of amphotericin B (Meizler Biopharma S/A, BR). The
SV-1 isolated from clinical specimens and was provided by the
epartamento de Virologia (IMPPG/UFRJ, BR) and the PV-1 (VR-58)gical Macromolecules 60 (2013) 93– 99
is an ATCC strain. The virus stocks were titered by plaque assay and
stored at −20 ◦C in 10% glycerol.
2.3. Cytotoxicity assay
The cytotoxicity of the compound in HEp-2 cells was evaluated
by MTT  (dimethylthiazolyldiphenyltetrazolium bromide) kit assay
(Sigma Chem. Co., USA), according to manufacturer’s speciﬁcations.
Brieﬂy, cell cultures grown at approximately 70% conﬂuence in
96-well microplates (TPP, Switzerland) were treated with varying
concentrations of the compound and incubated for 72 h at 37 ◦C. The
50% cytotoxic concentration (CC50) was calculated by regression
analysis, as the concentration of the substance capable of reducing
the optical density of MTT  product by 50% in comparison to control.
2.4. Antiviral activity of SPLCf
2.4.1. Plaque reduction assay (PRA)
The antiviral activity of SPLCf was evaluated by plaque reduc-
tion assay according to Melo et al. [22]. Brieﬂy, cell cultures
grown at approximately 100% conﬂuence in 24-well plates (TPP,
Switzerland) were treated with varying concentrations of the com-
pound (1500, 1000, 750 and 500 g/ml to HSV-1, and 10, 5, 2.5 and
1.25 g/ml to PV-1) under different protocols (time-of-addition
assay, inhibition of adsorption assay, inhibition of penetration assay
and virucidal assay). Brieﬂy, infected and treated cell cultures were
overlaid with nutrient agarose (DMEM 2×/1.8% agarose [v/v]) con-
taining 25 mM MgCl2 [23] and incubated for 40 h at 37 ◦C. Cells
were ﬁxed with 10% formaldehyde PBS, pH 7.3, and stained with
0.5% crystal violet in 20% ethanol. The percent of viral inhibition
(%VI) was calculated as: %VI = 1 − (PFU in treated cells/PFU in con-
trol cells)] × 100 [24], where, PFU is plaque forming unit. The 50%
inhibitory concentration (IC50) was  determined as the concentra-
tion of the substance capable of reducing the number of PFU in 50%,
by regression analysis. The selectivity index (SI) was expressed as
the ratio of CC50/IC50.
Time-of-addition assay: performed according to Faccin-Galhardi
et al. [25]. Varying concentrations of the compound were added
to cell cultures before (−1 h and −2 h), during (time 0 h) and after
(+1 h and +2 h) infection, followed by PRA.
Inhibition of adsorption assay: The cell cultures were pre-
incubated at 4 ◦C for 1 h and submitted to varying concentrations
of SPLCf simultaneously with viral infection. The cells were again
incubated at 4 ◦C for 1 h followed by PRA [26].
Inhibition of penetration assay: This test was  performed as
described by Cheng et al. [27] with minor modiﬁcations. The cells
were pre-incubated at 4 ◦C for 30 min, infected and maintained
at 4 ◦C for further 90 min  adsorption. The cultures were submit-
ted to concentrations of SPLCf and incubated at 37 ◦C for 10 min.
The cells were washed with PBS (pH 3) for 1 min  and immediately
neutralized with PBS (pH 11) followed by PRA.
Virucidal assay: Virus dilutions were incubated at 37 ◦C for 1 h
with varying concentrations of the compound (v/v), inoculated and
followed by PRA [28].
Zynvir (sodium acyclovir – ACV) (Novafarma Indústria Farma-
cêutica, Anápolis, GO, BR) and Interferon (INF) (Meizler Biopharma
S/A, SP, BR) were used as positive control for viral inhibition
(Table 4).
2.4.2. Immunoﬂuorescence assay (IFA)
The assay was performed according to Faccin et al. [29]. Brieﬂy,
cell cultures grown in 24-well plates with coverslips were infected
either with HSV-1 or PV-1, in the presence of varying concentra-
tions of the compound. Approximately, 18 h later cells were washed
with PBS (pH 7.3), ﬁxed with cold acetone and blocked with 2% pow-
dered skim milk PBS during 30 min. The cells were incubated either
f Biological Macromolecules 60 (2013) 93– 99 95
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Table 1
Assignment of the most important IR bands for C. ferrea sulfated polysaccharide
(SPLCf).
Wavenumber (cm−1) Assignment Reference
1255 vas (S O) ester sulfate [A,B]
1149 v (C O C) glycosidic
ether linkage
[C]
1045 v (C O) primary alcohol [C]
993  v (C O) in C O H of the
sugar composition
[C]
931 v (C O C) group of
galactopyranose
[E]
805  and 867 ı (C O S) group
associated to the
C O SO3
[D]
743  and 678 v (C S) group common to
C  S of sulfoxides
[F]N. Lopes et al. / International Journal o
ith mouse anti-HSV-1 (Santa Cruz Biotechnol., USA) or rabitt anti-
V-1 (INCQS, BR) followed by three washings with 0.05% Tween
0 PBS and incubated with goat anti-mouse IgG (HSV-1) or sheep
nti-rabbit IgG (PV-1) FITC conjugate (Sigma Chem. Co., USA). The
ells were examined in a Zeiss ﬂuorescence microscope (Zeiss Axio
mager.A1), 100 cells/coverslips were scored and the percentage of
uorescent cells inhibition calculated.
.4.3. Polymerase chain reaction (PCR)
The effect of SPLCf in HSV-1 DNA synthesis was performed
s described by Tal-Singer et al. [30]. Viral DNA of infected cells
2 × 106 cells) and treated with varying concentrations of the
ompound (150, 50, 25, 12.5 g/ml) were extracted using com-
ercial kits (QIAamp® DNA Mini and Blood Mini). Viral DNA from
nfected cells treated with acyclovir (3 mg/ml) (Zynvir–Novafarma
ndústria Farmacêutica, BR), viral DNA of infected cells without
PLCf treatment and DNA from noninfected cells and with-
ut treatment were used as controls. The primer pairs used
or ICP4 were ICP4F (5′GGCGGGAAGTTGTGGACTGG3′) and ICP4R
5′CAGGTTGTTGCCGTTTATTGCG3′). The reaction was  carried out in
 ﬁnal volume of 25 l containing 20 mM Tris–HCl (pH 8.4), 50 mM
Cl, 1.5 mM MgCl2, 0.2 mM of each dNTP, 2 pmol of each speciﬁc
rimer (*Invitrogen, Life Technologies, UK), 2.5 U of Taq DNA poly-
erase (*), and 5 l of extracted DNA. The program consisted of
enaturation at 94 ◦C for 4 min  and 40 cycles of denaturation at
4 ◦C for 1 min, annealing at 60 ◦C for 1 min, and polymerization at
2 ◦C for 1 min, followed by a ﬁnal extension for 7 min  at 72 ◦C. Ten
icroliters of the PCR products was resolved on a 12% polyacril-
mide gel. The expected sizes for ICP4 are 138 bp.
The effect of SPLCf in PV-1 RNA synthesis was  performed by
T-PCR, as described by Pliaka et al. [31]. Viral RNA of infected
nd treated cells (2 × 106 cells) with varying concentrations of the
ompound (10, 5, 2.5 and 1.25 g/ml) was extracted with com-
ercial kit (QIAamp® RNA Mini Kit). Viral RNA from infected cells
nd treated with human alfa-2B interferon (10,000 UI/ml) (Mei-
ler Biopharma S/A, BR), viral RNA of infected cells without SPLCf
reatment and RNA from noninfected cells and without treatment
ere used as controls. Initially, the reverse transcription was per-
ormed with a ﬁnal volume of reaction of 20 l. A ﬁrst reaction
ixture consisting of 5 pmol of random primers (*), 1 mM dNTP
*) and RNAse-free water up to a volume of 7 ml  was  prepared.
even microliters of the ﬁrst reaction was mixed with 5 l of the
xtracted viral RNA and incubated for 5 min  at 65 ◦C. Afterwards,
 second reaction mix  consisting of 1× M-MLV  reaction buffer,
.01 M DTT, 100 U M-MLV  Reverse Transcriptase (*) and RNAse-
ree water up to a volume of 8 l was prepared. Eight microliters of
he second reaction mixture was added to each sample and sequen-
ially incubated for 10 min  at 25 ◦C, 50 min  at 37 ◦C and 15 min  at
0 ◦C. The PCR reaction was carried out in a ﬁnal volume of 25 l
ontaining 0.4 mM dNTP, 2 pmol of each primer, 2.5 U of Taq DNA
olymerase with PCR buffer A (*) and cDNA. Speciﬁc primers for PV,
apsid gene (VP1–VP4) were 5′AGTTTCACCGAAGGCGGA3′ (F) and
′CGCTGACACAAAACCAAGGA3′ (R), resulting in a 102 bp ampli-
ed product. The PCR program consisted of denaturation at 95 ◦C
or 10 min, followed by 40 cycles of denaturation for 15 s at 95 ◦C,
nnealing at 60 ◦C for 1 min  and extension for 1 min  at 72 ◦C. The
nal cycle of extension was 7 min  at 72 ◦C. Ten-microliter aliquots
f the PCR products were resolved on a 12% polyacrylamide gel.
.4.4. HSV-1 cell-to-cell spread
The evaluation of HSV-1 cell-to-cell spread was performed
ccording to Ekblad et al. [32]. Cell cultures were submitted to con-
entrations of the SPLCf 1 h and 2 h after the infection and plaques
ere evaluated after, approximately, 40 h incubation. An average of[A]: Cerqueira et al., 2009; [B]: Peyman et al., 2011; [C]: Cerqueira et al., 2011; [D]:
Kalavelil, Joan, 1997; [E]: Souza et al., 2012; [F]: Nakanishi, Solomon, 1977.
10 plaques areas were estimated by digital image, using the Image
J software (http://rsb.info.nih.gov/ij/).
2.4.5. The combined synergistic potential of SPLCf with ACV for
HSV-1
The test was  performed according to Gong et al. [33] with minor
modiﬁcations. The SPLCf was  tested separately for four concen-
trations: 0.25 × IC50, 0.5 × IC50, 1.0 × IC50 and 2.0 × IC50, and the
ACV was  also tested separately for four concentrations: 0.25 × IC50,
0.5 × IC50, 1.0 × IC50 and 2.0 × IC50. The mixture of varying concen-
trations of SPLCf and ACV in a ﬁxed ratio, i.e., 0.25 × IC50 of SPLCf
combined with 0.25 × IC50 of ACV, added concomitantly to infec-
tion, was submitted to PRA. The degree of SPLCf and ACV interaction
was found by the combination index (CI) = CA/CB + IC50A/IC50B,
where CA and CB are the concentrations of the substances A and B
used in combination to achieve 50% effect, and IC50A and IC50B are
the inhibitory concentrations for the agents alone to cause the same
effect. A CI less than, equal to or greater than 1 indicates synergism,
additivity and antagonism, respectively [34].
2.5. Statistical analysis
Anova followed by Tukey’s test (BioEstat 5.0 for Windows XP,
2007) were applied to determine the difference among experi-
ments with the sulfated polysaccharide and control groups. Values
of p < 0.05 were considered signiﬁcant. The experiments were car-
ried out in triplicate.
3. Results
3.1. FT-IR spectroscopy
The FT-IR spectrum of SPLCf (Table 1), showed character-
istic bands of the presence of polysaccharides [35] relative
to the glycosidic ether linkage and primary alcohol, respec-
tively (1149 and 1045 cm−1), C O in C O H (993 cm−1) of the
galactomannans sugar composition [36], C O C group of 3,6-
anhydro--L-galactopyranose (931 cm−1) [37], C O S stretching
vibration (800–850 cm−1) [38], C S (743 cm−1 and 678 cm−1) [39].
The sulfatation was conﬁrmed by the presence of the band at
1255 cm−1 that refers to the asymmetrical stretching vibration
(S O) of the ester sulfate groups [35,40].3.2. 1H NMR and 13C NMR  spectroscopy from SPLCf
NMR  spectroscopy of 1H and 13C is an efﬁcient method to
analyze the structural features of polysaccharides [41]. 1H NMR
96 N. Lopes et al. / International Journal of Biological Macromolecules 60 (2013) 93– 99
Fig. 1. The inhibition of HSV-1 by C. ferrea sulfated polysaccharide (SPLCf) (%) for the following protocols: (a) time-of-addition (−2 to +2); (b) inhibition of adsorption (IA);
(c)  inhibition of penetration (IP) and (d) virucida (V) in HEp-2 cell cultures by plaque reduction assay, at the indicated concentrations. The percentage of viral inhibition (%VI)
was  determined in comparison to controls and the results are expressed as mean ± SD of triplicate independent experiments.
Table 2
Monosaccharides composition in Caesalpinia ferrea.
Monosaccharides Methods
13C NMR 1H NMR
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Table 4
The 50% inhibitory concentration (IC50) of C. ferrea sulfated polysaccharide (SPLCf),
acyclovir (ACV) and interferon (INF) for HSV-1 and PV-1 in HEp-2 cells, by plaque
assay. SPLCf, ACV and INF 50% cytotoxic concentrations (CC50) and the selectivity
index (SI) are also shown.
CC50 HSV-1 PV-1
IC50 SI IC50 SI
SPLCfa >3000 405 >7.4 1.73 >1734
ACVa 2550 2100 1,21 NT NT
INFb >1,000,000 NT NT 472 >2118.6
NT – not tested.
a
T
1d-Galactose 1.00 1.00
d-Mannose 2.57 2.02
pectrum of the sulfated polysaccharide (SPLCf) (spectra not
hown) showed signals (ı 4.73 and ı 5.01) corresponding to the
nomeric protons of -d-mannose and -d-galactose respectively.
he anomeric region of 13C NMR  (ı 100.17–101.48), which were
ssigned based on the literature [42] to G-1--d-galactopyranosyl,
 101.48 (for G1 residue), M-1--d-mannopyranosyl, ı 101.79
for M1  residue) and M-1--d-mannopyranosyl branched at O-6
 100.17 ppm (residual G-M1) [42]. The monosaccharides com-
osition of SPLCf in 1H NMR  and 13C NMR  is shown in Table 2.
n the DEPT NMR  spectrum (not shown), the signal at ı 68.03
an be attributed to the sulfation of CH2 at 6-O-substituted of -
alactopyranosyl [43]. The different carbon lines were well resolved
nd their chemical shifts were recorded in Table 3.
.3. Cytotoxic assay
The 50% cytotoxic concentration (CC50) of the sulfated polysac-
haride extracted from C. ferrea on HEp-2 cells was determined by
TT  assay. Table 4 shows the effect of SPLCf on HSV-1 and PV-1
eplication and its CC50 indicated as higher than 3000 g/ml. Thus
 very low or no toxicity can be assumed for this compound.
.4. Antiviral activity
SPLCf inhibited HSV-1 and PV-1 with an IC50 of 405 g/ml and
.73 g/ml, respectively, and selective index (SI) of >7.4 and >1734,
espectively (Table 4).
.4.1. Antiherpetic activity
The SPLCf showed great antiviral activity for HSV-1 when added
oncomitantly with viral infection (time 0 h). The %VI was  of 100%
or 1000 and 1500 g/ml, 84.1% for 750 g/ml, 70.8% for 500 g/ml,
8.4% for 250 g/ml. For the times 1 h and 2 h after infection, the %VI
as 100% for the two highest tested concentrations (1500 g/ml
nd 1000 g/ml). For 750 g/ml and 500 g/ml, the inhibition
as 89% and 39.1%, respectively, for the time 1 h, however, no
nhibition was observed for the time 2 h after infection (p > 0.05).
able 3
H and 13C NMR  chemical shifts for C. ferrea sulfated polysaccharide (SPLCf).
Unit 1H/13C chemical shift (ppm)
H1/C1 H2/C2 H3
-d-Galactopyranosyl 5.01/101.48 3.99/69.84 4.9
-d-Manopyranosyl 4.73/100.17 4.10/72.84 3.7g/ml.
b UI/ml.
However, the pre-treatment inhibited only 11% and 32% when the
compound was added 1 h and 2 h before the infection, respec-
tively, at the same concentrations (1000 g/ml and 1500 g/ml),
and with lower concentrations (750 g/ml and 500 g/ml) the
SPLCf caused no inhibition in the pre-treatments (p > 0.05). The
preincubation of virus suspensions with SPLCf showed an inac-
tivating effect about of 60% at the concentration of 1000 g/ml.
Along with the inhibition of adsorption, the inhibition of pene-
tration was also investigated. The results demonstrated that the
compound inhibited virus attachment in 54% and 77% at concen-
trations of 1000 g/ml and 1500 g/ml, respectively, and was not
able to prevent penetration of HSV-1 into the cells (p > 0.05) in all
tested concentrations (Fig. 1).
HSV-1 antigen expression was  repressed in the presence of
SPLCf at the concentrations of 500, 750, 1000 and 1500 g/ml in
a dose-dependent curve, representing the inhibition of 42.6%, 72%,
88.5% and 100%, respectively.
In addition, the effects of SPLCf on cell-to-cell spread of HSV-
1 was evaluated through viral plaques size measurement, and the
results showed that it reduced the lateral spread of infection at the
concentrations of 500 and 750 g/ml (Fig. 2).
Experiment to determine whether SPLCf could inhibit HSV DNA
synthesis was conducted to amplify HSV-1 ICP4 by PCR. Fig. 4A
shows a total reduction of the viral genomic DNA in the presence
of compound at the concentration of 150 g/ml.
The synergistic potential of the SPLCf with ACV for HSV-1 was
performed using four different combinations of SPLCf/ACV con-
centrations, 100/500; 200/1000; 400/2000 and 800/4000 g/ml.
All these combinations inhibited 100% of HSV-1 replication with
a CI < 0.5, demonstrated synergic effect.
/C3 H4/C4 H5/C5 H6/C6
4/78.84 3.99/71.35 3.80/67.92 3.80/62.54
4/71.87 4.10/76.41 4.45/78.03 3.88/61.98
N. Lopes et al. / International Journal of Biolo
Fig. 2. The effect of the C. ferrea sulfated polysaccharide (SPLCf) on the HSV-1 plaque
area. HEp-2 cell cultures were treated with SPLCf at the concentrations of 500 g/ml
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ind  750 g/ml, 1 h and 2 h after HSV-1 infection. The plaque area was determined
n comparison to controls and the results are expressed as mean ± SD of triplicate
ndependent experiments.
.4.2. Anti-poliovirus activity
The SPLCf showed even greater activity for PV-1, similarly
hen added concomitantly with viral infection, at low concentra-
ions (1.25–10 g/ml) with maximum %VI, approximately, 90% at
0 g/ml. When the compound was added before and after the
nfection the inhibition was observed albeit with lower %VI than
hat of the time 0 h. The SPLCf inhibited the PV-1 in approximately
ig. 3. The inhibition of PV-1 by C. ferrea sulfated polysaccharide (SPLCf) (%) for the follow
nhibition of penetration (IP) and (d) virucida (V) in HEp-2 cell cultures by plaque reduct
as  determined in comparison to controls and the results are expressed as mean ± SD of
ig. 4. The inhibition of C. ferrea sulfated polysaccharide (SPLCf) in the syntheses of H
lectrophoresis of (A) PCR amplicon for HSV-1 ICP4 (138 bp) and (B) RT-PCR amplicon for
nhibitor (ACV and INF).gical Macromolecules 60 (2013) 93– 99 97
10% and 40%, respectively, when added 1 h and 2 h before the infec-
tion (p > 0.05 for pre-treatments, except at the concentration of
10 g/ml in the treatment −2 h), and 30% for the post-treatments at
the highest concentration (10 g/ml). At the same concentration,
the inhibition of penetration, the inhibition of adsorption and viru-
cidal assay showed the respective %VI 28%, 38% and 48% (Fig. 3).
By IFA SPLCf demonstrated high percentages of the inhibition of
ﬂuorescent cells, 88% for 1.25 g/ml, 94% for 2.5 g/ml and 100%
for 1000 and 1500 g/ml when treatment was performed at the
time 0 h of infection. RT-PCR demonstrated that SPLCf caused a sig-
niﬁcant inhibition of viral RNA synthesis, as shown in Fig. 4B, at
the highest concentration (10 g/ml) and a dose-dependent curve
reduction is also shown.
4. Discussion
In this work, the effect of a sulfated polysaccharide obtained
from C. ferrea seeds aqueous extract was  investigated against HSV-
1 and PV-1 replication. This plant is widely used in Brazilian popular
medicine and most of the studies have focused on its high content
of polyphenols and the analgesic, anti-inﬂammatory, antiulcer and
cancer chemopreventive properties [44–47]. This work is the ﬁrst
report of the antiviral effect of C. ferrea.  We  investigated the mech-
anism by which the SPLCf exerted the antiviral activity by its ability
to prevent viral replication, viral attachment or its direct effect on
virus particles.
The anti-HSV-1 activity might be mainly attributed to the
polyanionic character of SPLCf. Since the simultaneous and pos-
treatment were more efﬁcient, a direct inactivation of viral particles
or inhibition of virus replication at the initial phases of the viral
replication cycle could be involved. In particular, it has been shown
ing protocols: (a) time-of-addition (−2 to +2); (b) inhibition of adsorption (IA); (c)
ion assay, at the indicated concentrations. The percentage of viral inhibition (%VI)
 triplicate independent experiments.
SV-1 and PV-1 nucleic acids, at the indicated concentrations. Polyacrilamide gel
 PV-1 VP1–VP4 (102 bp). MW std. (M) and controls for virus (VC); cell (CC); positive
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hat sulfated polysaccharides are potent inhibitors of HSV binding
o host cells and are competitors of viral glycoproteins receptors
48,49]. In addition, virucidal effect has been suggested for these
ubstances leading to solubilization of virus envelope or inducing
hemical modiﬁcation, degradation or masking essential envelope
roteins [50]. Our study demonstrated that SPLCf did not inter-
ere with HSV-1 penetration stage. The inhibition of viral protein
ynthesis shown by IFA is in accordance with the results obtained
y plaque reduction assay, in that SPLCf inhibited HSV-1 repli-
ation when used simultaneously to or after the infection. PCR
roduct demonstrated a massive inhibition at the concentration of
50 g/ml evidencing that the SPLCf beyond the effect previously
hown is able to reduce viral DNA synthesis.
On the ground of HSV-1 cytophatic effect, we found that SPLCf
igniﬁcantly reduced HSV-1 plaque area. Since an efﬁcient dissemi-
ation of virus has an important role in its infectivity, the inhibition
f cell-to-cell propagation is an attractive target for new antiviral
rugs. The inhibition of HSV-1 cell-to-cell dissemination is a possi-
ility, however, a decrease in the rate of virus replication caused by
PLCf cannot be ruled out. Recently, Cardozo et al. [51] have shown
he inhibition of HSV cell-to-cell spread by a sulfated polysaccha-
ide from Agaricus brasiliensis mycelium.
Regarding the synergistic effect of SPLCf and ACV against HSV-
, the results demonstrated a cooperative effect suggesting that
PLCf can be used either alone or in combination with ACV for the
reatment of the infection.
The inhibition of PV-1 replication occurred by similar mecha-
ism to that found for HSV-1, however, more effectively at lower
oncentrations of the compound. Similarly, it is suggested inhi-
ition at early stages of PV-1 replication. The inhibition of PV-1
enetration and adsorption are also in agreement with blockage
f initial steps of the replication, even though, the direct effect on
irus particles is a possibility, as shown by virucidal assay. More-
ver, some studies have reported the antiviral effect of sulfated
olysaccharides after virus internalization into the cell. These com-
ounds could interfere in the synthesis of viral proteins [52,53]. Our
esults demonstrated by the IF assay, a high percentage of inhibition
n the number of ﬂuorescent cells, conﬁrming the results of plaque
eduction assay and suggesting a dose-dependent inhibition of PV-
 protein synthesis. On the other hands, the RT-PCR demonstrated
n inhibition of viral RNA synthesis in the highest concentration
10 g/ml) showed a dose-dependent inhibition as in the PRA.
This work has provided the ﬁrst experimental evidence of
he antiviral properties of sulfated polysaccharide from aqueous
xtract of C. ferrea fruits for HSV-1 and PV-1. Our ﬁndings indicated
hat SPLCf interfered with several stages of the HSV replication
ycle, mainly in the step of virus adsorption, as well as, the effect on
irus particles and in the expression of viral protein. The inhibitory
ffect of the compound in the replication of PV-1 was stronger and
nterfered with early steps of virus replication, such as, the step
f viral adsorption and penetration, and in the synthesis of viral
olyprotein. In conclusion, our ﬁndings suggested that SPLCf is a
romising compound for the development of new antivirals and
urther studies are encouraging to get insight into its the mecha-
ism of action and potentiality.
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